NYSE · ANRO

Alto Neuroscience, Inc.

Healthcare · Biotechnology

$30.78▲ 0.49% ($0.15)at close

As of 4:00 PM ET

52-week

$3.77$37.48

Market cap

$1.08B

P/E

Valuation

Recommended · Earnings yield

Price used

$30.78

Earnings yield

Unavailable

Reported earnings

10-year Treasury benchmark: 4.97%

USD · Financial statements through 2026-06-30 · EPS source period not supplied

A positive earnings figure and a usable price are needed to calculate earnings yield.

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 22, 2026, 8:00 PM UTC
Financial statement period: Financial statements through 2026-06-30 · EPS source period not supplied
Data refreshed: Sep 23, 2026, 1:13 AM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Is there enough operating history to anchor a DCF? Only 2 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 673.37%FCF (TTM): -21.59%

What changed

The stock rose 673.37% over the last year. Free cash flow declined 21.59% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications.

CEOAmit Etkin

SectorHealthcare

IndustryBiotechnology

Employees68

IPO dateFeb 2, 2024

https://www.altoneuroscience.com

Market multiples

Forward P/E—

EV/EBITDA-5.68

Enterprise value$341.49M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-49.17%▼7.4ppvs FY2025

Analyst consensus

RatingBuy

Target price$38.00▲23.46%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est -$0.67 · Revenue est —

View